Rhenium 188 NM 02 therapeutic - NanoMab
Alternative Names: 188Re NM-02; 188Re-NM-02 - NanoMab/University Hospital Aachen; 188Re-NM-02 - University Hospital Aachen/NanoMabLatest Information Update: 28 Jun 2024
At a glance
- Originator NanoMab
- Class Antibacterials; Antibodies; Antineoplastics; Radioisotopes
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric cancer; HER2 positive breast cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Gastric-cancer in China (SC)
- 28 Jun 2024 No recent reports of development identified for research development in HER2-positive-breast-cancer in China (PO)
- 12 Apr 2022 NM 02 antibody licensed to Radipharm Theranostics